Interleukin-2 receptor-targeted fusion protein with diphtheria toxin data

SRGN (Hopkinton, Mass.) reported on a total of 23 patients now entered in an ongoing, open-label, Phase

Read the full 177 word article

How to gain access

Continue reading with a
two-week free trial.